Mode
Text Size
Log in / Sign up

Fine-mapping analysis identifies thousands of genetic variants contributing to coronary artery disease risk in over one million individuals.

Fine-mapping analysis identifies thousands of genetic variants contributing to coronary artery disea…
Photo by digitale.de / Unsplash
Key Takeaway
Consider these genetic associations as statistical priorities for research rather than validated causal mechanisms for immediate clinical intervention.

This genome-wide association study (GWAS) fine-mapping analysis utilized summary statistics from over one million individuals of European ancestry to investigate genetic contributions to coronary artery disease (CAD) risk. The primary objective was to estimate the number of genetic variants influencing CAD susceptibility and to prioritize causal candidates through fine-mapping techniques.

The analysis estimated that, on average, 34,000 variants contribute to CAD risk, collectively explaining 3.8% of the total phenotypic variance. Among these, 36 high-confidence variants (posterior inclusion probability > 0.9) were identified, which collectively explained 13.6% of the genetic variance. Additionally, 17,150 variants were prioritized within 581 high-confidence local credible sets, and 195 variants were successfully annotated to specific genes. Downstream pathway analyses implicated 170 variants.

The most influential variants were mapped to the genes PHACTR1, APOE, and LPL, explaining 2.49%, 1.59%, and 1.46% of the genetic variance respectively. The study advances causal understanding of CAD genetics but does not establish experimental proof of causation for specific variants. No adverse events or safety data were reported, as this was a genomic analysis rather than a clinical trial. Key limitations include the reliance on statistical fine-mapping of summary data and the restriction to European ancestry populations. These findings represent genetic associations and prioritized causal variants, not experimentally validated mechanisms, and are not immediately applicable to clinical practice or personalized prevention.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Genomics offer a powerful approach to identify causal mechanisms underlying coronary artery disease (CAD) risk, with implications for pathogenesis, personalized prevention strategies, and therapeutic target discovery. Functionality-informed genome-wide fine mapping was performed using the Bayesian framework SBayesRC to estimate genetic contributions of 6.9 million common variants, based on GWAS summary statistics from over one million individuals of European ancestry. Causal candidate genes were prioritized in a 5kB flanking window within high-confidence local credible sets (LCSs). Their downstream biological influence was analyzed using protein-protein interaction networks and pathway enrichment analyses across three complimentary dimensions: molecular, cellular, and disease level. Genetic modeling captured the highly polygenic architecture of CAD, estimating on average 34,000 variants to contribute to CAD risk, explaining 3.8% of total phenotypic variance. 36 high-confidence variants (PIP > 0.9) collectively explained 13.6% of genetic variance, while most variants demonstrated small individual effects but with substantial collective contributions. 17,150 variants were prioritized within 581 high-confidence LCSs, of which 195 were annotated to genes and 170 were implicated in downstream pathway analyses. The three most influential variants were mapped to PHACTR1, APOE, and LPL, explaining 2.49%, 1.59%, and 1.46% of genetic variance respectively. Pathway analyses revealed that genetic risk in CAD is driven by dysregulation of three interlinked biological processes: 1) lipoprotein function and cholesterol metabolism, 2) vascular homeostasis, and 3) cellular stress responses and inflammation. These findings advance the causal understanding of CAD pathogenesis, supporting the transition from association-based to functionality-informed genomic approaches in cardiovascular genetics.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.